Cambridge, Mass. – November 3, 2020 – Biogen (Nasdaq: BIIB) today announced it will host a webcast of its prerecorded presentation related to the study design of the ongoing EMBARK re-dosing study for its Alzheimer’s disease investigational therapy, aducanumab, as well as a live, virtual question and answer (Q&A) session at the upcoming CTAD 2020 digital conference.
Webcast Details:
- Wednesday, November 4, 2020, 10:15 a.m. ET – EMBARK: A Phase 3b, open-label, single-arm, safety study to evaluate the long-term safety and efficacy of aducanumab in eligible participants with Alzheimer’s disease and Q&A with Carmen Castrillo-Viguera, M.D., Medical Director, Clinical Development at Biogen
The EMBARK re-dosing study was initiated in March 2020, in line with Biogen’s commitment to offer aducanumab to eligible patients who were previously in aducanumab clinical studies. EMBARK is a global re-dosing clinical study designed to evaluate aducanumab in eligible Alzheimer’s disease patients who were actively enrolled in aducanumab studies (PRIME, EVOLVE, EMERGE, and ENGAGE) as of March 2019.
To access the webcast and live Q&A session, please go to the Investors section of Biogen’s website at investors.biogen.com. An archived version of the webcast will be available following the presentation.
About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain.
We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
About Aducanumab
Aducanumab (BIIB037) is an investigational human monoclonal antibody studied for the treatment of Alzheimer’s disease. Based on clinical data from patients with Mild Cognitive Impairment due to Alzheimer’s disease and mild Alzheimer’s disease, aducanumab has the potential to impact underlying disease pathophysiology, slow cognitive and functional decline and provide benefits on patients’ ability to perform activities of daily living, including conducting personal finances, performing household chores, such as cleaning, shopping and doing laundry, and independently traveling out of the home. If approved, aducanumab would be the first treatment to meaningfully change the course of the disease for individuals living with Alzheimer’s.
Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement. Since October 2017 Biogen and Eisai have collaborated on the development and commercialization of aducanumab globally.
| MEDIA CONTACT: David Caouette + 1 617 679 4945 public.affairs@biogen.com |
INVESTOR CONTACT: Joe Mara +1 781 464 2442 IR@biogen.com |
